<DOC>
	<DOCNO>NCT02323906</DOCNO>
	<brief_summary>CC-122-HCC-001 Phase 1b dose escalation expansion clinical study CC-122 combination sorafenib subject unresectable HCC receive prior systemic therapy HCC . The dose escalation phase study explore several dose level CC-122 combination sorafenib , follow expansion part study use optimal combination dose regimen .</brief_summary>
	<brief_title>Safety Efficacy Study CC-122 Combined With Sorafenib Primary Liver Cancer</brief_title>
	<detailed_description>The primary objective study determine safety tolerability CC-122 administer orally combination sorafenib , define non-tolerated dose ( NTD ) , maximum tolerate dose ( MTD ) , recommend phase 2 dose ( RP2D ) . The secondary objective study determine preliminary efficacy CC-122 combination sorafenib , base response Evaluation Criteria Solid Tumors ( RECIST 1.1 )</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Subject understand voluntarily sign inform consent document prior conduct study relate assessments/procedures 2 . Subject 18 year age time sign Informed Consent Form 3 . Subject confirm pathologic diagnosis Hepatocellular carcinoma accord American Association Study Liver Diseases Guidelines.A biopsy perform screening may serve diagnostic biopsy subject radiographic diagnosis . 4 . Subject unresectable stage B ( intermediate ) , C ( advance ) Hepatocellular carcinoma accord Barcelona Clinic Liver Cancer staging.Stage B subject must progress , eligible curative resection , transplantation , embolic , ablative therapy 5 . Subject least one measurable lesion accord Response Evaluation Criteria Solid Tumors version 1.1 . Evaluable target lesion may treat local therapy ; previously treat lesion may evaluate target lesion lesion available show objective definite progression prior treatment . Local therapy must complete least four week prior baseline tumor evaluation 6 . Satisfactory archival tumor biopsy tissue retrieve , new tumor biopsy perform , prior start Cycle 1 7 . Subject life expectancy 12 week 8 . Subject Eastern Cooperative Oncology Group Performance Status 0 1 9 . Subject ChildPugh score le 7 ( ie , class A better ) neither encephalopathy clinically significant ascites ( ascites require paracentesis within 3 month sign ICF exclude ) . ChildPugh status calculate base clinical finding laboratory result screen period . 10 . Subject follow laboratory parameter screen : Adequate hematologic function include : 1 . Absolute Neutrophil Count least 1.5 x 109/L 2 . Platelets least 75,000 x 106/L 3 . Hemoglobin least 9 g/dL 4. International Normalized Ratio least 1.7 Adequate hepatic function include : 1 . Serum aspartate aminotransferase alanine aminotransferase least 5 time upper limit normal 2 . Serum total bilirubin least 3 mg/dL 3 . Serum albumin least 2.8 g/dL Note : Laboratories combination must still Child Pugh score le 7 Other laboratory parameter : 1 . Serum creatinine least 1.5 time upper limit normal 2 . Potassium within normal range correct supplement 11 . For subject know suspected cirrhosis , esophagogastroduodenoscopy ) within 12 month sign informed consent form , show evidence untreated varix stigmata active bleeding ( active ulcer , visible vessel , blood ) require . Subjects history upper GI bleeding must EGD 3 month less prior signing consent form confirm adequate prior endoscopic therapy ( eg , evidence untreated varix , recent active bleeding , stigma suggest high risk bleeding , active ulcer ) . Subjects history/suspected esophageal varix must optimal medical management ( eg , proton pump inhibitor nonselective betablocker ) per local institutional policy . 12 . Subject able adhere study visit schedule protocol requirement 13 . Pregnancy Prevention Risk Management Plan 1 . Females childbearing potential must undergo pregnancy test base frequency outline Pregnancy Prevention Risk Minimization Plan pregnancy result must negative . 2 . Unless practice complete abstinence heterosexual intercourse , sexually active FCBP must agree use adequate contraceptive method specify Pregnancy Prevention Risk Minimization Plan . Complete abstinence acceptable case prefer usual lifestyle subject . Periodic abstinence ( calendar ovulation , symptothermal , postovulation method ) withdrawal acceptable . 3 . Males ( include vasectomy ) must use barrier contraception ( condom ) engage sexual activity Female Childbearing Potential specify Pregnancy Prevention Risk Minimization Plan . 4 . Males must agree donate semen sperm 3 month last dose CC122 . 5 . All subject must : Understand CC122 could potential teratogenic risk . Agree abstain donate blood take CC122 sorafenib follow discontinuation use . Agree share either study drug another person . 6 . Other subject , Female Childbearing Potential male able father child handle CC122 touch capsule , unless glove wear . 7 . Be counseled pregnancy precaution risk fetal exposure 1 . Subject receive previous systemic therapy Hepatocellular carcinoma include sorafenib , chemotherapy investigational agent 2 . Subject receive local anticancer therapy ≤ 4 week prior baseline tumor evaluation 3 . Subject undergone major surgery within last 4 week minor surgery within last 2 week prior sign Informed Consent Form recover surgery 4 . Subject receive investigational drug therapy disease Hepatocellular carcinoma within last 4 week 5 halflives , whichever short , prior signing Informed Consent Form 5 . Subject complete radiation treatment le 2 week prior sign Informed Consent Form 6 . Subject receive last dose αinterferon , ribavirin , sofobuvir and/or antiviral therapy Hepatitis C Virus ( HCV ) less 4 week prior sign Informed Consent Form 7 . Subject clinically significant bleeding , include bleed esophageal/gastric varix within ≤ 3 month sign informed consent form , require transfusion , surgical procedure hospitalization . Esophageal varix treat accord local standard practice ( eg , ligation banding procedure complete ≤ 3 month prior sign inform consent form ) . See Inclusion Criterion 10 8 . Subjects require therapeutic anticoagulation either warfarin low molecular weight heparin . Low dose low molecular weight heparin catheter maintenance permit 9 . Subject tumor invasion stomach duodenum 10 . Subject histologic proof fibrolamellar carcinoma 11 . Subjects know symptomatic brain metastasis 12 . Subject persistent diarrhea due malabsorptive syndrome ( celiac sprue inflammatory bowel disease ) malabsorption ≥ National Cancer Institute Common Terminology Criteria Adverse Events ( CTCAE , Version 4.03 ) Grade 2 , despite medical management , significant GI disorder could affect absorption either study drug 13 . Subject history concurrent second cancer require active , ongoing systemic treatment . 14 . Subject known history human immunodeficiency virus ( HIV ) seropositivity ( HIV test mandatory ) 15 . Subject peripheral neuropathy least NCI CTCAE Grade 2 16 . Subject history persistent skin rash least NCI CTCAE Grade 2 17 . Subject impaired cardiac function clinically significant cardiac disease include follow : 1 . LVEF ( leave ventricular ejection fraction ) 45 % le determined MUGA ( multigated acquisition ) ECHO ( Echocardiogram ) 2 . Complete leave bundle branch bifascicular block 3 . Congenital long QT syndrome 4 . Persistent clinically meaningful ventricular arrhythmia 5 . QTcF great 460 msec Screening ECG ( mean triplicate recording ) 6 . Unstable angina pectoris myocardial infarction le 6 month prior start either study drug 7 . Uncontrolled hypertension ( blood pressure great 140/90 mmHg least 2 measurement sequential visit , despite blood pressure medication ) Subjects baseline blood pressure 140/90 mmHg eligible must optimal medication blood pressure management h. TroponinT value upper limit normal BNP great 100 pg/mL 18 . Subject acute chronic active infectious disorder uncontrolled nonmalignant illness whose control , opinion investigator , may jeopardize complication study therapy . Chronic hepatitis B C virus ( HBV HCV ) except ( ie , eligible study ) ; HBV require antiviral therapy 19 . Subject undergone liver transplantation solid organ transplantation require immunosuppression 20 . Subject receive chronic treatment systemic corticosteroid potentially immunosuppressive agent . Intermittent topical local injection corticosteroid oral/IV aldosterone mineralocorticoid allow 21 . Subjects history nonhealing wound ulcer , bone fracture less 3 month prior fracture 22 . Subject treat concomitant strong CYP3A4 inducer St. John 's Wort , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , phenobarbital . The use concomitant strong CYP3A4 inducer may decrease sorafenib plasma concentration must avoid . 23 . Subject female pregnant breast feed 24 . Subject unwilling unable comply protocol , opinion investigator 25 . Subject significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study 26 . Subject condition confounds ability interpret data study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatocellular</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Phase 1</keyword>
	<keyword>CC-122</keyword>
	<keyword>Sorafenib ,</keyword>
	<keyword>Nexavar</keyword>
	<keyword>Unresectable Hepatocellular Carcinoma</keyword>
	<keyword>Unresectable HCCAdvanced ,</keyword>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>liver cancer</keyword>
</DOC>